Education
About Us
Working with TipRanks
Follow Us
Glaukos (GKOS)
NYSE:GKOS
Earnings Data
Report Date
Oct 29, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.26Last Year’s EPS
-0.28Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with record net sales and significant growth in key segments, notably the U.S. glaucoma franchise and international markets. However, challenges remain with MAC LCDs affecting the MIGS market and potential impacts from proposed CMS reimbursement changes. The anticipated transition from Photrexa to Epioxa also presents potential disruptions. Overall, the positive achievements and strategic advancements outweigh the challenges faced.Company Guidance -
Q3 2025
Record Second Quarter Net Sales
Glaukos reported record second quarter consolidated net sales of $124.1 million, up 30% on a reported basis and 29% on a constant currency basis compared to the previous year.
Strong U.S. Glaucoma Franchise Growth
The U.S. glaucoma franchise delivered record second quarter net sales of $72.3 million, marking a significant year-over-year growth of 45%.
iDose TR Adoption and Utilization
iDose TR sales reached approximately $31 million in the second quarter, showcasing strong commercial momentum supported by positive clinical outcomes.
Increased Full Year 2025 Sales Guidance
The company raised its full year 2025 net sales guidance to $480 million to $486 million, up from the previous range of $475 million to $485 million.
International Glaucoma Franchise Performance
International glaucoma franchise achieved record net sales of $31.3 million, a year-over-year growth of 20% reported and 15% constant currency basis.
Corneal Health Pipeline Progress
The FDA's ongoing NDA review for Epioxa, the next-generation corneal cross-linking therapy, is progressing with a targeted PDUFA date of October 20, 2025.
Operational and Strategic Investments
The company made strategic investments with the acquisition of Mobius Therapeutics and the purchase of an additional building at its headquarters.
GKOS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GKOS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jul 30, 2025 | $94.05 | $86.09 | -8.46% |
Apr 30, 2025 | $94.25 | $83.54 | -11.36% |
Feb 20, 2025 | $157.36 | $125.88 | -20.01% |
Nov 04, 2024 | $131.38 | $127.86 | -2.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Glaukos (GKOS) report earnings?
Glaukos (GKOS) is schdueled to report earning on Oct 29, 2025, After Close (Confirmed).
What is Glaukos (GKOS) earnings time?
Glaukos (GKOS) earnings time is at Oct 29, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GKOS EPS forecast?
GKOS EPS forecast for the fiscal quarter 2025 (Q3) is -0.26.